Status:
RECRUITING
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Lead Sponsor:
AbbVie
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease ac...
Detailed Description
B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) or BCMA antibody-drug conjugate (ADC) are allowed.
Eligibility Criteria
Inclusion
- Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1.
- Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol.
- All participants must have measurable diseases per central laboratory as outlined in protocol
Exclusion
- Has received prior etentamig treatment.
- Prior exposure to BCMA-targeted therapy as noted in the protocol.
- Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).
Key Trial Info
Start Date :
August 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2036
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT06896916
Start Date
August 7 2025
End Date
March 1 2036
Last Update
December 26 2025
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Beverly Hills Cancer Center /ID# 266921
Beverly Hills, California, United States, 90211
2
Colorado Blood Cancer Institute /ID# 273751
Denver, Colorado, United States, 80218
3
Washington University /ID# 266972
St Louis, Missouri, United States, 63110
4
Rutgers Cancer Institute of New Jersey /ID# 266833
New Brunswick, New Jersey, United States, 08901